[{"address1": "451 D Street", "address2": "5th Floor Suite 501", "city": "Boston", "state": "MA", "zip": "02210", "country": "United States", "phone": "(857) 209-0050", "website": "https://elicio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph node\u0096targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node\u0096targeted AMP peptide vaccine in preclinical studies for the treatment of mutant b-raf murine sarcoma viral oncogene homolog B1-driven cancers; and ELI-008, a multivalent lymph node\u0096targeted AMP peptide vaccine in preclinical studies for use in the treatment of mutated tumor protein p53 expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 32, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert T. Connelly", "age": 64, "title": "CEO, President & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 943020, "exercisedValue": 0, "unexercisedValue": 137562}, {"maxAge": 1, "name": "Dr. Allen Richard Nissenson F.A.S.N., FACP, M.D.", "age": 77, "title": "Founder & Independent Director", "yearBorn": 1947, "fiscalYear": 2024, "totalPay": 48125, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Peter  DeMuth Ph.D.", "age": 37, "title": "Chief Scientific Officer", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 648600, "exercisedValue": 0, "unexercisedValue": 54705}, {"maxAge": 1, "name": "Dr. Christopher M. Haqq M.D., Ph.D.", "age": 58, "title": "Executive VP, Head of Research & Development and Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 721087, "exercisedValue": 0, "unexercisedValue": 86025}, {"maxAge": 1, "name": "Dr. Darrell J. Irvine Ph.D.", "title": "Co-Founder, Consultant, Board Observer & Chairman of Scientific Advisory Board", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Preetam  Shah M.B.A., Ph.D.", "age": 51, "title": "Chief Strategy & Financial Officer and Treasurer", "yearBorn": 1973, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Megan C. Filoon", "title": "General Counsel, Secretary & Compliance Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Esther  Welkowsky", "title": "Senior Vice President of Clinical Development", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Joy  Seymour", "title": "VP & Head of Regulatory Affairs", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Thian  Kheoh Ph.D.", "title": "Senior Vice President of Biometrics", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 9.94, "open": 10.07, "dayLow": 9.7337, "dayHigh": 10.1075, "regularMarketPreviousClose": 9.94, "regularMarketOpen": 10.07, "regularMarketDayLow": 9.7337, "regularMarketDayHigh": 10.1075, "payoutRatio": 0.0, "beta": 2.153, "forwardPE": -3.828794, "volume": 49558, "regularMarketVolume": 49558, "averageVolume": 51858, "averageVolume10days": 80230, "averageDailyVolume10Day": 80230, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 160768880, "fiftyTwoWeekLow": 3.7, "fiftyTwoWeekHigh": 10.75, "fiftyDayAverage": 8.7451, "twoHundredDayAverage": 6.89025, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 153440480, "profitMargins": 0.0, "floatShares": 10640361, "sharesOutstanding": 16338300, "sharesShort": 416956, "sharesShortPriorMonth": 346951, "sharesShortPreviousMonthDate": 1751241600, "dateShortInterest": 1753920000, "sharesPercentSharesOut": 0.026099999, "heldPercentInsiders": 0.42957002, "heldPercentInstitutions": 0.09495, "shortRatio": 11.15, "shortPercentOfFloat": 0.0404, "impliedSharesOutstanding": 16338300, "bookValue": 0.113, "priceToBook": 87.07965, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -54612000, "trailingEps": -3.98, "forwardEps": -2.57, "lastSplitFactor": "1:10", "lastSplitDate": 1685664000, "enterpriseToEbitda": -3.457, "52WeekChange": 1.1484716, "SandP52WeekChange": 0.15005577, "quoteType": "EQUITY", "currentPrice": 9.84, "targetHighPrice": 13.0, "targetLowPrice": 12.0, "targetMeanPrice": 12.5, "targetMedianPrice": 12.5, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 2, "totalCash": 22088000, "totalCashPerShare": 1.353, "ebitda": -44383000, "totalDebt": 14902000, "quickRatio": 2.226, "currentRatio": 2.277, "debtToEquity": 812.541, "returnOnAssets": -1.23261, "returnOnEquity": -600.1319, "freeCashflow": -20259500, "operatingCashflow": -35087000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ELTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Elicio Therapeutics, Inc.", "longName": "Elicio Therapeutics, Inc.", "corporateActions": [], "postMarketTime": 1755290007, "regularMarketTime": 1755288001, "exchange": "NCM", "messageBoardId": "finmb_214936128", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "regularMarketChangePercent": -1.00603, "regularMarketPrice": 9.84, "marketState": "CLOSED", "esgPopulated": false, "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 51858, "fiftyTwoWeekLowChange": 6.1400003, "fiftyTwoWeekLowChangePercent": 1.6594595, "fiftyTwoWeekRange": "3.7 - 10.75", "fiftyTwoWeekHighChange": -0.90999985, "fiftyTwoWeekHighChangePercent": -0.08465115, "fiftyTwoWeekChangePercent": 114.84716, "earningsTimestampStart": 1754942400, "earningsTimestampEnd": 1755288000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -3.98, "epsForward": -2.57, "epsCurrentYear": -2.17, "priceEpsCurrentYear": -4.534562, "fiftyDayAverageChange": 1.0949001, "fiftyDayAverageChangePercent": 0.12520155, "twoHundredDayAverageChange": 2.94975, "twoHundredDayAverageChangePercent": 0.4281049, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Angion Biomedica Corp.", "nameChangeDate": "2025-08-15", "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1612535400000, "postMarketChangePercent": 0.00406087, "postMarketPrice": 9.8404, "postMarketChange": 0.00039959, "regularMarketChange": -0.0999994, "regularMarketDayRange": "9.7337 - 10.1075", "displayName": "Elicio Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-08-16"}]